GoodRx

GoodRx offers a suite of services that aims to provide easy access to price transparency and affordability solutions for medications, convenient telehealth consultations, and additional healthcare resources. 

A notable feature of GoodRx is its prescription price comparison platform, which provides consumers with price comparisons and negotiated prices on prescriptions through its mobile applications. Additionally, GoodRx has expanded its offerings to include medication savings programs, medical provider consultations, lab tests through its telehealth offerings HeyDoctor and the GoodRx Telehealth Marketplace, and other healthcare-related content. The company offers both free and subscription-based services. The primary service, which provides discounts and price comparisons on prescription medications, is available free to all users. Additionally, GoodRx offers a premium membership program called GoodRx Gold, which is subscription-based and offers even greater discounts on medications and healthcare services for a monthly fee.

The company went public in September 2020. As of February 2024, the company’s shares were publicly traded under the ticker symbol GDRX on NASDAQ, with a market capitalization of USD 2.6 billion. In March 2022, GoodRx acquired technology and services platform vitaCare Prescription Services from TherapeuticsMD for USD 150 million. By acquiring vitaCare, GoodRx aimed to enhance the prescription process from beginning to end, ensuring patients have access to and can afford their essential brand-name medications.

Key customers and partnerships

GoodRx serves a broad spectrum of customers, including individuals looking to save on prescription medications and healthcare providers seeking cost-effective solutions for their patients.

In October 2023, GoodRx partnered with Navitus Health Solutions to launch Savings Connect, aimed at providing even greater prescription savings. Earlier in July 2023, the company also collaborated with CVS Caremark to introduce Caremark Cost Saver, a program designed to help lower pharmacy out-of-pocket drug costs for CVS Caremark clients' members.

Funding and financials

In September 2020, GoodRx secured a private placement of USD 100 million from Silver Lake, a growth equity investor. The investment was aimed at enhancing the company’s position as it was preparing to go public. Later that month, the company raised USD 1.1 billion during its IPO at an offer price of USD 33 per share​.

In 2022, GoodRx reported revenue of USD 766.6 million, reflecting a 2.8% growth from the previous year. During the year, the company’s adjusted EBITDA stood at USD 213.5 million, whilst the company incurred a net loss of USD 32.8 million. However, in 2023, the company reported that its revenue was down 2.1% from 2022 amounting to USD 750.3 million. During that year, the company suffered a net loss of USD 8.87 million.